Donald Abrahm, MD
Gastroenterology · Newport Beach, CANPI 1215022405
Payments from drug & device makers
Across 426 payments — averaging $122.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$37K
- Pfizer$5K
- AbbVie$3K
- Johnson & Johnson$908
- Boston Scientific$888
- Takeda Pharmaceuticals U.S.A., Inc.$589
- plus $4K from 29 others
What the payments were for
- Consulting fees$4,2008%
- Speaking & faculty fees$35,31468%
- Travel & lodging$1,0602%
- Food & beverage$11,54322%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 35 | $37,344 |
| Pfizer | 37 | $5,186 |
| AbbVie(2 entities) | 141 | $3,356 |
| Johnson & Johnson | 59 | $908 |
| Boston Scientific | 10 | $888 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $589 |
| Steris Corporation | 4 | $560 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $523 |
| Sanofi | 14 | $376 |
| Cook Medical LLC | 3 | $372 |
| Madrigal Pharmaceuticals | 8 | $327 |
| Lilly USA, LLC | 6 | $241 |
| Lucid Diagnostics Inc. | 2 | $239 |
| ERBE USA Inc | 1 | $178 |
| Bristol Myers Squibb | 10 | $159 |
| Medtronic | 1 | $143 |
| Endogastric Solutions, Inc | 1 | $116 |
| Covidien LP | 2 | $100 |
| Conmed Corporation | 1 | $100 |
| Micro-tech Endoscopy USA, Inc. | 1 | $63 |
| Vivus LLC | 3 | $47 |
| Gilead | 3 | $42 |
| Shionogi Inc | 2 | $30 |
| Braintree Laboratories, Inc. | 2 | $27 |
| Novo Nordisk | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Biosense Webster, Inc. | 1 | $21 |
| Olympus America Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $20 |
| Intercept Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Celltrion USA Inc. | 1 | $17 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELARA$37,185
- XELJANZ$4,629
- TRUFREEZE$560
- Skyrizi$366
- ECHOTIP INSIGHT$255
- ERBE$178
- Resolution 360 ULTRA Clip$159
- Barrx$143
- Rinvoq$125
- OMVOH$120
- Hemospray$117
- AXIOS$117
- ESOPHYX$116
- CONMED BILIARY$100
How this compares
$52,117 in reported general payments places this provider in the 85th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 38 | $1,116,656 |
| Humira(Cf) PenAdalimumab | 14 | $186,424 |
| LinzessLinaclotide | 143 | $90,236 |
| Mesalamine | 69 | $72,281 |
| XifaxanRifaximin | 18 | $38,519 |
| CreonLipase/Protease/Amylase | 27 | $35,834 |
| VemlidyTenofovir Alafenamide | 24 | $35,471 |
| Dexlansoprazole DrDexlansoprazole | 65 | $16,367 |
| Balsalazide Disodium | 75 | $12,549 |
| DexilantDexlansoprazole | 19 | $8,164 |
| Pantoprazole Sodium | 696 | $7,104 |
| Budesonide EcBudesonide | 18 | $4,098 |
| Colesevelam Hcl | 42 | $3,822 |
| Sucralfate | 40 | $3,271 |
| Lubiprostone | 21 | $2,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $908 | $1,116,65638 claims |
| AbbVieLinzess, Creon | $3,356 | $126,070170 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $523 | $38,51918 claims |
| GileadVemlidy | $42 | $35,47124 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $589 | $8,16419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,885 gastroenterology providers in California.
Other gastroenterology in Newport Beach
- Kenneth ChangNewport Beach$1.3M
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.